IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Virtu Financial LLC

Virtu Financial LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 302.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,574 shares of the medical research company’s stock after acquiring an additional 11,701 shares during the quarter. Virtu Financial LLC’s holdings in IQVIA were worth $3,293,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. First Foundation Advisors lifted its holdings in shares of IQVIA by 3.8% in the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock valued at $245,000 after purchasing an additional 43 shares during the last quarter. Team Hewins LLC boosted its holdings in shares of IQVIA by 5.0% in the first quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 46 shares during the period. Invera Wealth Advisors LLC increased its holdings in shares of IQVIA by 0.3% in the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock valued at $3,183,000 after acquiring an additional 46 shares during the period. Covestor Ltd raised its position in IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 48 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund grew its position in IQVIA by 0.3% during the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after purchasing an additional 48 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IQV has been the topic of a number of research reports. Robert W. Baird raised their price target on IQVIA from $235.00 to $251.00 and gave the stock a “neutral” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. boosted their target price on IQVIA from $260.00 to $288.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Barclays increased their price target on IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday, July 23rd. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, Royal Bank of Canada initiated coverage on shares of IQVIA in a report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $266.67.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 1.60% of the stock is owned by corporate insiders.

IQVIA Stock Performance

IQV opened at $239.38 on Tuesday. The stock’s 50 day simple moving average is $238.59 and its 200 day simple moving average is $234.21. The stock has a market cap of $43.64 billion, a P/E ratio of 32.70, a P/E/G ratio of 2.24 and a beta of 1.49. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. During the same quarter in the prior year, the company earned $2.22 earnings per share. IQVIA’s revenue was up 2.3% compared to the same quarter last year. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.25 EPS for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.